2277-93-2 Usage
Uses
Used in Organic Synthesis:
Bicyclo[2.2.2]octane1,4diaMine dihydrochloride is used as a reagent in organic synthesis for its ability to facilitate various chemical reactions. Its bicyclic structure and solubility in multiple solvents make it a versatile component in the creation of complex organic molecules.
Used in Pharmaceutical Production:
In the pharmaceutical industry, bicyclo[2.2.2]octane1,4diaMine dihydrochloride is used as a building block for the preparation of various pharmaceuticals. Its unique structure contributes to the development of new drugs and medicinal compounds, enhancing the range of treatments available for different health conditions.
Used in Laboratory Research:
Bicyclo[2.2.2]octane1,4diaMine dihydrochloride is an important intermediate in laboratory settings, where it is employed for conducting a wide array of chemical reactions. Its presence in research environments is crucial for the advancement of scientific knowledge and the discovery of new chemical processes and compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 2277-93-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,2,7 and 7 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 2277-93:
(6*2)+(5*2)+(4*7)+(3*7)+(2*9)+(1*3)=92
92 % 10 = 2
So 2277-93-2 is a valid CAS Registry Number.
2277-93-2Relevant academic research and scientific papers
PEPTIDASE INHIBITORS
-
Page/Page column 34, (2010/10/19)
The present invention relates to a series of novel compounds having the formula: [INSERT FORMULA I] wherein A is a bicyclic carbocycle and R?1? and R?2? are independently [INSERT MOLECULE FROM CLAIM 1] The compounds are useful as DPP-IV inhibitors and for treating diabetes.
PEPTIDASE INHIBITORS
-
Page/Page column 41-42, (2010/10/19)
The present invention relates to a series of novel compounds having the formula (I) wherein: X is NR3 or O; n is 1 or 2; A is a bicyclic carbocycle and R1 and R1 are as described herein. The compounds are useful as DPP-IV inhibitors, such as for the treatment of diabetes.
